SOLICITATION NOTICE
65 -- Positive Blood Sample Sets in Support of COVID-19
- Notice Date
- 12/16/2022 12:40:12 PM
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- NIAID-NOI-2150063
- Response Due
- 12/27/2022 1:00:00 PM
- Point of Contact
- Lu Chang, Phone: 2406273034
- E-Mail Address
-
lu-chang.lu@nih.gov
(lu-chang.lu@nih.gov)
- Description
- The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with MedStar Health Research Institute Inc. (Medstar Washington Hospital Center), 6525 Belcrest Road, Suite 700, Hyattsville, Maryland 20782-2031 is to continue to acquire the quantity of thirty (30) positive blood sample sets in support of COVID from the CALYPSO study. This acquisition will be processed under FAR Part 12- Acquisition for Commercial Items and will be made pursuant to the authority in FAR Part 13.501(a)(1). Only one award will be made as a result of this solicitation, which is firm-fixed price. Delivery is one (1) year from date and acceptance of award to Bethesda, Maryland 20892.� The NIAID�s HIV Pathogenesis Section of the Laboratory Of Immunoregulation (LIR) focuses research effort on the elucidation of cellular and molecular mechanisms of the regulation of the human immune response in health and disease.� Due to the current CoV pandemic, Program�s focus has shifted to try to understand the mechanisms of pathogenesis of CoV as it pertains to lymphopenia and the role of lymphocytes in disease outcomes and to coagulopathy and high inflammatory cytokine levels and their role in prognosis.� Program has collaborated with Medstar Washington Hospital Center and received positive blood sample sets in support of COVID-19.� Medstar Washington Hospital Center screen their patients to identify those who are CoV positive enroll in the CALYPSO study, and have provided positive blood samples for Program�s pathogenesis studies.� Only MedStar Washington Hospital Center provides these particular types of COVID-19 blood samples from their research project.� Using COVID blood samples from outside of this study may jeopardize or inhibit NIAID�s current research.� In order to ensure best comparison between existing and new data is to avoid using other potential blood samples from vendors that is not Medstar Washington Hospital Center. The statutory authority for this sole source requirement is 41 U.S.C. 253 (c) (1) as implemented by FAR 6.302-1 only one source available, no substitutions possible.� THIS IS NOT A SOLICITATION FOR COMPETITIVE QUOTATIONS.� All responsible sources that could provide positive blood sample sets in support of COVID from the CALYPSO study submit a capability statement that will be considered by email (subject line to reference NIAID-NOI-2150063) to Lu-Chang Lu at lu-chang.lu@nih.gov , by 4pm standard time (EST) time December 27, 2022.� A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.� Any responses received by NIAID after this date and exact time specified is late and will not be considered.�
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/96d9d63091de423480f870f9ec735a6f/view)
- Place of Performance
- Address: Bethesda, MD 20892, USA
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN06545957-F 20221218/221216230101 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |